Semaglutide For Sale — Research-Grade GLP-1
Semaglutide is the most researched GLP-1 receptor agonist peptide in metabolic science — independently tested to ≥99% purity via HPLC and Mass Spectrometry. Available in lyophilized powder and nasal spray for research use. Free shipping over $100.
Third-Party COA
GLP-1 Agonist
USA Manufactured
Free Shipping $100+
Ships Same Day
Research Compound Overview
What Is Semaglutide? The World’s Most Studied GLP-1 Peptide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic analogue of human GLP-1 with approximately 94% sequence homology. It was developed by Novo Nordisk and has become the most commercially successful and scientifically studied peptide in metabolic research history, with FDA-approved applications under the brand names Ozempic (diabetes) and Wegovy (obesity).
PureRawz offers semaglutide for sale strictly as a research peptide for in vitro and preclinical laboratory use. Every batch is independently verified to ≥99% purity via HPLC and Mass Spectrometry by MZ Biolabs, with a batch-specific Certificate of Analysis published publicly on every product page.
PureRawz semaglutide is sold exclusively for laboratory research purposes. It is not the same as prescription Ozempic or Wegovy. It is not compounded, not for human injection, and not intended for weight loss use. Researchers purchasing for in vitro or animal model studies must comply with all applicable institutional and regulatory requirements.
Semaglutide Product Specifications
| Compound Name | Semaglutide (NN9535, OG217SC) |
| Class | GLP-1 Receptor Agonist (GLP-1 RA) |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4113.58 g/mol |
| CAS Number | 910463-68-2 |
| GLP-1 Homology | ~94% with human GLP-1 |
| Purity (PureRawz) | ≥99% HPLC verified |
| Testing Lab | MZ Biolabs (independent, third-party) |
| Half-Life | ~7 days (due to albumin binding) |
| Available Forms | Lyophilized Powder · Nasal Spray |
| Intended Use | Research purposes only — not for human use |
Mechanism of Action
How Semaglutide Works — The GLP-1 Pathway
Semaglutide’s mechanism is one of the most studied in modern metabolic research. Understanding its pathway is essential for designing accurate preclinical protocols.
Available Formats
Semaglutide For Sale in Multiple Research Forms
PureRawz offers research-grade semaglutide in two delivery formats. Both forms use the same ≥99% purity compound with batch-specific COA documentation.
Freeze-dried semaglutide in sealed glass vials. Reconstitute with bacteriostatic water. Stable 24+ months at −20°C. The standard format for subcutaneous preclinical research protocols. Available in 2mg, 5mg, 10mg, and bulk 20mg vials for extended research programs.
Research-grade semaglutide in intranasal delivery format. Designed for protocols examining mucosal GLP-1 receptor engagement and systemic bioavailability via the nasal route. No reconstitution required. Consistent dosing per spray.
GLP-1 Comparison
Semaglutide vs Tirzepatide vs Liraglutide — Which GLP-1 Research Compound?
Semaglutide is the most studied GLP-1 agonist but is frequently compared to tirzepatide and liraglutide in metabolic research literature. The table below summarizes key distinctions.
| Factor | Semaglutide | Tirzepatide | Liraglutide |
|---|---|---|---|
| Receptor Target | GLP-1 only | GLP-1 + GIP (dual) | GLP-1 only |
| Half-Life | ~7 days | ~5 days | ~13 hours |
| Dosing Frequency | Once weekly | Once weekly | Once daily |
| Weight Reduction (clinical) | ~15–17% body weight | ~22% body weight | ~5–8% body weight |
| Cardiovascular Data | Extensive (SUSTAIN, SOUL) | Growing (SURMOUNT) | Moderate (LEADER) |
| Neuro / CNS Research | Alzheimer’s, addiction data | Emerging | Limited |
| Research Maturity | Most extensive | Rapidly growing | Well established |
| PureRawz Price | From $49.99 | From $54.99 | From $39.99 |
All products sold as research compounds only. Not for human use. Clinical data referenced from published peer-reviewed sources.
Why PureRawz
Why Researchers Buy Semaglutide From PureRawz
Semaglutide’s popularity has spawned a market of counterfeit and low-purity research products. PureRawz holds three non-negotiable standards that set it apart.
Every semaglutide batch is tested by MZ Biolabs — accredited, independent, third-party. The COA is published publicly, searchable by lot number. For a compound this complex, independent verification is non-negotiable.
HPLC and Mass Spectrometry confirm purity and sequence integrity on every batch. Semaglutide is a 31-amino acid modified peptide — impurities in complex peptides are harder to detect and more research-critical than with small molecules.
Manufactured and fulfilled from a US facility. Orders before 2PM EST ship same business day. All peptide orders are cold-packed where required and shipped in discreet, unmarked packaging.
Semaglutide purity is critical. The massive demand for semaglutide has created a supply of low-quality, underdosed, or misidentified products in the research compound market. A batch-specific COA from an independent laboratory is the only verification that holds. PureRawz publishes every COA, every batch — lot-number searchable on every product page.
Research Overview
Semaglutide Research: Beyond Weight Loss
The clinical research on semaglutide extends far beyond its well-known weight management applications. The preclinical and clinical literature reveals a compound with broad biological activity across multiple organ systems. The following covers research context only. Semaglutide is not recommended for self-administration.
Primary Research Areas
-
Metabolic & Glycemic Research: The foundational research area — semaglutide’s glucose-dependent insulin secretion and glucagon suppression mechanism has been studied in type 2 diabetes models across SUSTAIN 1–10 clinical trials, establishing it as the most clinically validated GLP-1 agonist.
-
Obesity & Body Composition: The STEP clinical trial program established semaglutide’s ~15–17% body weight reduction profile in obesity research — the most extensively documented weight reduction data for any peptide compound to date.
-
Cardiovascular Protection: The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in overweight/obese subjects without diabetes — one of the most significant cardiovascular outcomes in metabolic peptide research.
-
Neurological & Alzheimer’s Research: GLP-1 receptors are expressed throughout the brain. Emerging preclinical and early human data suggest semaglutide may reduce neuroinflammation and amyloid accumulation — an area of rapidly expanding research interest in 2026.
-
Addiction & Reward Pathway Research: 2024–2025 clinical data revealed semaglutide users reported significant reductions in alcohol, nicotine, and opioid cravings — triggering a wave of preclinical research into GLP-1’s role in dopamine reward pathways.
-
Liver & NAFLD Research: Semaglutide has demonstrated significant reductions in hepatic fat content in NASH/NAFLD models, with Phase III trials showing liver fibrosis improvement — an emerging and clinically significant research direction.
-
Kidney Protection: The FLOW trial (2024) demonstrated semaglutide significantly slows chronic kidney disease progression in type 2 diabetes patients — a landmark finding expanding its research scope to nephrology.
-
Inflammation & Immune Modulation: Preclinical data shows GLP-1 receptor activation reduces systemic inflammatory markers including CRP, IL-6, and TNF-α — positioning semaglutide as a subject of interest in broader inflammatory disease research.
Research Reference
Semaglutide Research Dosage Reference — Preclinical & Clinical Data Only
The following summarizes dosage ranges from published preclinical and clinical research. For reference only. Not a recommendation for human use.
| Research Protocol | Reported Dose | Route | Duration (Studies) |
|---|---|---|---|
| Glycemic Research (rodent) | 3–30 nmol/kg | SC injection | Acute – 28 days |
| Obesity / Body Weight (STEP trials) | 0.25–2.4 mg/week | SC injection | 68 weeks |
| T2D Glycemic Control (SUSTAIN) | 0.5–1 mg/week | SC injection | 30–104 weeks |
| Cardiovascular (SELECT trial) | 2.4 mg/week | SC injection | ~34 months |
| Neurological / CNS (preclinical) | 10–240 nmol/kg | IP or SC | Variable |
| NAFLD / Liver Research | 0.1–0.4 mg/week (Phase II) | SC injection | 72 weeks |
Data sourced from peer-reviewed preclinical and clinical literature. Semaglutide requires a prescription for human therapeutic use. Research compound use must comply with all applicable regulations.
Frequently Asked Questions
Semaglutide For Sale — Buyer FAQs
Reviews
There are no reviews yet.